Table 1.
Patient Demographics, Ocular Parameters, Tumor Growth and Outcomes of Intravtireal Bevacizumab Injection or Transpupillary Thermotherapy on Subfoveal Fluid Associated with Small Pigmented Choroidal Lesions
| Patient No. | Age range / Sex | Primary therapy #No. | SFF resolution | Additional therapy | Orange pigment | Foveal distance (mm) | Disc distance(mm) | Initial BCVA (Snellen) | BCVA change, Last BCVA (Snellen) | FU (mo) | Initial LBD (mm) | Initial height (mm) | Tumor growth, Last LBD (mm) *Last height (mm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50–60/F | IVB #3 | None | Refused | Yes | 5 | 3.1 | 20/40 | Worse, HM | 79 | 7.4 | 2.8 | ↑↑↑, 9.34*10.1 |
| 2 | 40–50/F | IVB #6 | None | Brachy Tx. | Yes | 0 | 2.8 | 20/50 | Worse, HM | 18 | 6.12 | 1.94 | ↑↑↑, 8.16*5.22 |
| 3 | 50–60/M | IVB #2 | Complete | Enucleation | Yes | 0 | 0 | 20/200 | Worse, LP- | 48 | 5.29 | 2.06 | ↑↑↑, 7.76*3.87 |
| 4 | 30–40/M | IVB #2 | None | Yes | 0 | 2.2 | 20/50 | Stable | 68 | 5.59 | 1.64 | → | |
| 5 | 50–60/M | IVB #2 | None (Spontaneous resolution after 30 mo Obs.) | Yes | 1.6 | 0 | 20/40 | Improved, 20/20 | 59 | 4.4 | 2.08 | → | |
| 6 | 30–40/F | IVB #2 | None (Spontaneous resolution after 15 mo Obs.) | Yes | 0 | 2.4 | 20/25 | Worse, 20/63 | 19 | 3.11 | 1.28 | → | |
| 7 | 30–40/M | IVB #1 | Complete | No | 2.1 | 5 | 20/32 | Improved, 20/20 | 74 | 8.38 | 2.86 | → | |
| 8 | 60–70/F | IVB #4 | Partial | No | 0 | 1.6 | 20/63 | Stable | 36 | 4.1 | 0.45 | → | |
| 9 | 30–40/F | IVB #4 | Partial | Yes | 0 | 0 | 20/25 | Worse, 20/40 | 39 | 5.88 | 2.38 | → | |
| 10 | 40–50/F | IVB #3 | None | TTT #2 | Yes | 0 | 1.8 | 20/40 | Worse, 20/63 | 72 | 6.25 | 1.92 | ↑, 6.67*2.62 |
| 11 | 60–70/F | IVB #1 | None | TTT #3 / Brachy Tx. | Yes | 0.5 | 0 | 20/63 | Worse, 20/125 | 51 | 6.81 | 2.23 | ↑, 7.24*2.52 |
| 12 | 30–40/F | (1) IVB #1 (3) IVB #2 (5) IVB #2 | None | (2)TTT #2 (4)TTT #1 / Brachy Tx. | Yes | 0 | 0 | 20/100 | Worse, HM | 42 | 7.11 | 1.91 | ↑↑↑, 10.63*4.12 |
| 13 | 40–50/F | IVB #2 | None | TTT #3 / Brachy Tx. | No | 1.1 | 1.1 | 20/25 | Worse, 20/200 | 11 | 7.74 | 2.17 | ↑, 9.08*4.09 |
| 14 | 30–40/M | IVB #3 | Partial | TTT #2 | No | 0.8 | 3.6 | 20/200 | Stable | 54 | 6.2 | 1.1 | → |
| 15 | 20–30/M | TTT #4 | Complete | Yes | 0 | 3 | 20/63 | Improved, 20/25 | 86 | 7.17 | 2.24 | ↓, 3.96*0.7 |
|
| 16 | 50–60/M | TTT #2 | Complete | No | 0.75 | 0 | 20/40 | Improved, 20/20 | 30 | 4 | 1.9 | ↓, 3.94*1.38 |
|
| 17 | 40–50/F | TTT #1 | Partial | No | 0 | 0 | 20/200 | Stable | 22 | 7.1 | 1.96 | → | |
| 18 | 30–40/M | TTT #1 | Complete | No | 3.5 | 2.7 | 20/63 | Improved, 20/40 | 3 | 4.72 | 2.42 | Very short FU | |
| 19 | 50–60/M | Obs. | Spontaneous resolution | Yes | 0.6 | 2.9 | 20/40 | Stable | 36 | 4.33 | 2.24 | → |
IVB intravitreal bevacizumab injection, TTT transpupillary thermotherapy, No. number, SFF subfoveal fluid, BCVA best corrected visual acuity, FU Follow-up duration, mo months, LBD largest base diameter, M male, F female, Obs. Observation, Tx. Therapy, HM hand motion, LP- no light perception